HKG:1513

4 stories mentioning HKG:1513Updated 6d ago

Every FINWIRES story that references HKG:1513, newest first.

Livzon Receives China Drug Registration Certificate for Decoction Granules for Phlegm; Hong Kong Shares Slide 3%

Livzon Pharmaceutical (SHE:000513, HKG:1513) received a drug registration certificate from China's National Medical Products Administration for its Banxia Baizhu Tianma decoction granules, according to a Friday disclosure to the Shanghai bourse.The traditional Chinese drug is indicated for wind-phlegm disturbance syndrome, helping resolve phlegm. The drug formula is widely used in dizziness, headache, nausea, and vomiting.Shares fell 3% in Hong Kong during afternoon trading on Friday.

HKG:1513SHE:000513

Asia59d ago

Livzon Pharma Unit Wins China Approval for Fertility Drug Biosimilar

Livzon Pharmaceutical's (HKG:1513, SHE:000513) unit Livzon MABPharm received approval from China's National Medical Products Administration for Recombinant Human Follitropin Alfa Solution for Injection, according to a Monday Hong Kong bourse filing.The product is indicated for anovulation, including polycystic ovary syndrome, ovarian stimulation in assisted reproductive technology procedures, and certain patients with severe luteinizing hormone and follicle-stimulating hormone deficiencies.The drug is administered through a pre-filled injection pen and was developed as a biosimilar.

HKG:1513SHE:000513

Asia59d ago

Livzon Pharmaceutical Drug Accepted for China Review

Livzon Pharmaceutical Group (HKG:1513) said Chinese regulators accepted its marketing authorization application for the lecankitug injection jointly developed with Beijing Xinkanghe Biopharmaceutical Technology, according to a Monday filing with the Hong Kong bourse.The medicine is aimed at treating adult patients with active ankylosing spondylitis, a chronic inflammatory rheumatic and immune-mediated disease.

HKG:1513

Asia111d ago

Livzon Pharmaceutical Gets China Nod for Trial of Helicobacter Pylori Drug

Livzon Pharmaceutical Group's (SHE:000513, HKG:1513) obtained approval to conduct a clinical trial of JP-1366 Tablet from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approval is for the indication of the combination of the drug with appropriate antibiotics for the eradication of Helicobacter pylori.

HKG:1513SHE:000513

Track with the FINWIRES app suite

FolioX

Track HKG:1513 in your portfolio

WheelAI

Analyze HKG:1513 options with the wheel strategy

StockInsider

See market sentiment on HKG:1513